Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HannaH: SC vs IV Trastuzumab in HER2+ Early Breast Cancer
NCT00950300Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2009
- Primary completion
- Jul 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of trastuzumab in HER2-positive breast cancer, sponsored by Roche. Started Oct 2009; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00950300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00950300.